Analysis of Anti-mycotic Agents
In recent years, side-effects associated with bone marrow or organ transplantation or declining immunity levels in patients due to cancer chemotherapy or HIV infection have led to an increase in profound (systemic or internal organ) infections.In response to these problems, a large number of anti-bacterial agents offering a broad spectrum of anti-bacterial efficacy are now under development.
Among these, azole-based anti-mycotic agents, owing to their high selectivity, are widely used in the form of oral administration or injection. However, because such agents are metabolized by cytochrome P450 in the liver and present many drug interactions, to prevent side-effects when administered concurrently with other drugs, there is a need to monitor their in-blood concentration.
The text below describes examples of analyzing azole-based anti-mycotic agents (ketoconazole, hydroxyl itraconazole, and itraconazole).
Analysis of anti-mycotic agents
azole-based anti-mycotic agents (ketoconazole, hydroxyl itraconazole, and itraconazole).
5310 Column Oven
5420 UV-VIS Detector
Empower2 Data Processing System
|Column||HITACHI LaChrom C18 (3 µm) (4.6 mmI.D. x 100 mm)|
|Elute||(A) 10 mM KH2PO,K2HPO4(pH 7.0)/CH4CN = 50/50
*Gradient: 0min (B) 10% → 0min (B) 50%
|Flow rate||1.0 mL/min|
|Injection vol.||20 µL|
Results of standard sample measurement
These data are an example of measurement; the individual values cannot be guaranteed.
The system is for research use only, and is not intended for any animal or human therapeutic or diagnostic use.
In order to read a PDF file, you need to have Adobe® Reader®